IRS1 and metabolic syndrome: Similarly, EVs miR-222 inhibits the insulin receptor substrate 1 (IRS1) gene, impairing glucose uptake in skeletal muscle and hepatocytes, suggesting its potential as a therapeutic target for obesity-induced metabolic syndrome and T2D [108,109].